#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest

#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest

Publication date: May 13, 2019

This post was originally published on this site Early, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in the presentation, -One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. ” The CHORDS trial (NCT02637856) is evaluating whether Ocrevus (ocrelizumab, marketed by Genentech) might be an effective therapy for RRMS patients who had not responded well to an -adequate course” of other MS therapies. -Findings from this interim analysis of all 608 patients at one year of follow-up support the effectiveness of Ocrevus” in treating people with a suboptimal response to other DMTs, Leist concluded. The post #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest appeared first on Multiple Sclerosis News Today.

Concepts Keywords
B Cells Magnetic resonance imaging
Biogen MRI
Brain Biogen
Canada Glatiramer acetate
Disability Ocrelizumab
Fatigue Genentech
Genentech Breakthrough therapy
Genzyme Drugs
Glatiramer Acetate Life sciences
Headache Biotechnology
Inflammation Multiple sclerosis
Infusion Upper respiratory infection
Magnetic Resonance Imaging Urinary tract infection
MRI Active inflammation
Multiple Sclerosis Headache fatigue
Nasal Multiple sclerosis
PhD Magnetic resonance imaging
Pregnancy Suboptimal prior disease
Relapse
Sanofi
Upper Respiratory Infection
Urinary Tract Infection

Semantics

Type Source Name
disease MESH infection
disease MESH Sclerosis
drug DRUGBANK Nonoxynol-9
disease MESH inflammation
disease MESH development
gene UNIPROT LARGE1
gene UNIPROT CYREN
drug DRUGBANK Glatiramer
drug DRUGBANK Dimethyl fumarate
drug DRUGBANK Fingolimod
drug DRUGBANK Teriflunomide
drug DRUGBANK Antithymocyte immunoglobulin (rabbit)
disease DOID urinary tract infection
disease MESH urinary tract infection
gene UNIPROT PDC
disease MESH relapsing-remitting multiple sclerosis
drug DRUGBANK Ocrelizumab
disease DOID multiple sclerosis
disease MESH disease progression
disease MESH multiple sclerosis
gene UNIPROT SLC35G1
disease MESH relapses
disease DOID RRMS

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *